Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott Laboratories : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
01/17/2020 | 09:15am EST

The company will report its earnings for FY 2019 on 01/22/2020. Generally, the company reports earnings worse than estimates. In recent months, the 7 analysts from Standard & Poor's consensus have revised their EPS estimates downward.


© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
02/11ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
02/05WALL STREET STOCK EXCHANGE : Tiffany is part of LVMH, Tesla gives some bad news,..
02/04ABBOTT LABORATORIES : Gets FDA Breakthrough Designation for Fully Implantable He..
DJ
02/04ABBOTT : 's In-Development Fully Implantable Heart Pump System Earns FDA's Break..
PR
02/03ABBOTT : Announces First-of-Its-Kind Trial to Assess New Therapy Option for Peop..
PR
01/31ABBOTT LABORATORIES : Tendyne device receives world's first ce mark for transcat..
AQ
01/30ABBOTT : 's Tendyne™ Device Receives World's First CE Mark for Transcathet..
PR
01/27ABBOTT LABORATORIES : Receives expanded indication from the u.s. fda for directi..
AQ
01/24Abbott Laboratories Gets Expanded Indication for Infinity Deep Brain Stimulat..
DJ
01/24ABBOTT : Receives Expanded Indication From the U.S. FDA for Directional Deep Bra..
PR
More news
Financials (USD)
Sales 2020 34 120 M
EBIT 2020 7 754 M
Net income 2020 4 460 M
Debt 2020 10 170 M
Yield 2020 1,56%
P/E ratio 2020 35,5x
P/E ratio 2021 28,9x
EV / Sales2020 4,95x
EV / Sales2021 4,49x
Capitalization 159 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,28  $
Last Close Price 89,66  $
Spread / Highest target 22,7%
Spread / Average Target 10,7%
Spread / Lowest Target -13,0%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President & Chief Operating Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES3.22%158 560
MASIMO CORPORATION16.14%9 841
NOVOCURE LIMITED10.55%9 220
ASAHI INTECC CO., LTD.-1.27%7 389
PENUMBRA, INC.15.93%6 649
GETINGE-2.93%4 816